{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:45:50Z","timestamp":1790815550676,"version":"4.1.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1038\/s41375-021-01157-w","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T10:10:19Z","timestamp":1613556619000},"page":"2508-2516","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome"],"prefix":"10.1038","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0525-4766","authenticated-orcid":false,"given":"Takashi","family":"Taga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9446-9568","authenticated-orcid":false,"given":"Daisuke","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiminori","family":"Terui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0061-9781","authenticated-orcid":false,"given":"Tsutomu","family":"Toki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7710-2449","authenticated-orcid":false,"given":"Shotaro","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3136-5670","authenticated-orcid":false,"given":"Hidefumi","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3226-556X","authenticated-orcid":false,"given":"Takako","family":"Miyamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Hashii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5471-7646","authenticated-orcid":false,"given":"Hiroshi","family":"Moritake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-113X","authenticated-orcid":false,"given":"Hideki","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8763-0280","authenticated-orcid":false,"given":"Hiroyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Taki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0168-2475","authenticated-orcid":false,"given":"Etsuro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7582-0201","authenticated-orcid":false,"given":"Asahito","family":"Hama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0476-4978","authenticated-orcid":false,"given":"Katsuyoshi","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiichiro","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko M.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souichi","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1520-7007","authenticated-orcid":false,"given":"Daisuke","family":"Tomizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"key":"1157_CR1","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1182\/blood-2017-01-765057","volume":"129","author":"M Uffmann","year":"2017","unstructured":"Uffmann M, Rasche M, Zimmermann M, von Neuhoff C, Creutzig U, Dworzak M, et al. Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial. Blood .2017;129:3314\u201321.","journal-title":"Blood"},{"key":"1157_CR2","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1182\/blood-2017-01-764324","volume":"129","author":"JW Taub","year":"2017","unstructured":"Taub JW, Berman JN, Hitzler JK, Sorrell AD, Lacayo NJ, Mast K, et al. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children\u2019s Oncology Group AAML0431 trial. Blood .2017;129:3304\u201313.","journal-title":"Blood"},{"key":"1157_CR3","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/pbc.25789","volume":"63","author":"T Taga","year":"2016","unstructured":"Taga T, Watanabe T, Tomizawa D, Kudo K, Terui K, Moritake H, et al. Preserved high probability of overall survival with significant reduction of chemotherapy for myeloid leukemia in Down syndrome: a nationwide prospective study in Japan. Pediatr Blood Cancer. 2016;63:248\u201354.","journal-title":"Pediatr Blood Cancer"},{"key":"1157_CR4","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2012-03-414755","volume":"120","author":"T Taga","year":"2012","unstructured":"Taga T, Saito AM, Kudo K, Tomizawa D, Terui K, Moritake H, et al. Clinic al characteristics and outcome of refractory\/relapsed myeloid leukemia in children with Down syndrome. Blood. 2012;120:1810\u20135.","journal-title":"Blood"},{"key":"1157_CR5","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1200\/JCO.2003.08.060","volume":"21","author":"AS Gamis","year":"2003","unstructured":"Gamis AS, Woods WG, Alonzo TA, Buxton A, Lange B, Barnard DR, et al. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children\u2019s Cancer Group Study 2891. J Clin Oncol. 2003;21:3415\u201322.","journal-title":"J Clin Oncol"},{"key":"1157_CR6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3324\/haematol.2013.089425","volume":"99","author":"M Blink","year":"2014","unstructured":"Blink M, Zimmermann M, von Neuhoff C, Reinhardt D, de Haas V, Hasle H, et al. Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study. Haematologica. 2014;99:299\u2013307.","journal-title":"Haematologica"},{"key":"1157_CR7","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","volume":"11","author":"JE Rubnitz","year":"2010","unstructured":"Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11:543\u201352.","journal-title":"Lancet Oncol"},{"key":"1157_CR8","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1182\/blood-2003-02-0390","volume":"102","author":"G Xu","year":"2003","unstructured":"Xu G, Nagano M, Kanezaki R, Toki T, Hayashi Y, Taketani T, et al. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood .2003;102:2960\u20138.","journal-title":"Blood"},{"key":"1157_CR9","doi-asserted-by":"publisher","first-page":"4631","DOI":"10.1182\/blood-2010-05-282426","volume":"116","author":"R Kanezaki","year":"2010","unstructured":"Kanezaki R, Toki T, Terui K, Xu G, Wang R, Shimada A, et al. Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia. Blood. 2010;116:4631\u20138.","journal-title":"Blood"},{"key":"1157_CR10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/gcc.22816","volume":"59","author":"K Terui","year":"2020","unstructured":"Terui K, Toki T, Taga T, Iwamoto S, Miyamura T, Hasegawa D, et al. Highly sensitive detection of GATA1 mutations in patients with myeloid leukemia associated with Down syndrome by combining Sanger and targeted next generation sequencing. Genes Chromosomes Cancer. 2020;59:160\u20137.","journal-title":"Genes Chromosomes Cancer"},{"key":"1157_CR11","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1182\/blood-2012-02-408336","volume":"120","author":"MR Loken","year":"2012","unstructured":"Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA, et al. Residual disease detected by multidimensional flowcytometry signifies high relapse risk in patients with de novo acute myeloid leukemia:a report from Children\u2019s Oncology Group. Blood 2012;120:1581\u20138.","journal-title":"Blood"},{"key":"1157_CR12","doi-asserted-by":"publisher","first-page":"5442","DOI":"10.1200\/JCO.2007.12.3687","volume":"25","author":"K Kudo","year":"2007","unstructured":"Kudo K, Kojima S, Tabuchi K, Yabe H, Tawa A, Imaizumi M, et al. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2007;25:5442\u20137.","journal-title":"J Clin Oncol"},{"key":"1157_CR13","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/j.1365-2141.2006.06097.x","volume":"133","author":"A Al-Ahmari","year":"2006","unstructured":"Al-Ahmari A, Shah N, Sung L, Zipursky A, Hitzler J. Long-term results of an ultra low-dose cytarabine-based regimen for the treatment of acute megakaryoblastic leukaemia in children with Down syndrome. Br J Haematol. 2006;133:646\u20138.","journal-title":"Br J Haematol"},{"key":"1157_CR14","doi-asserted-by":"publisher","first-page":"e27942","DOI":"10.1002\/pbc.27942","volume":"66","author":"K Nakashima","year":"2019","unstructured":"Nakashima K, Hasegawa D, Tomizawa D, Miyamura T, Hama A, Iwamoto S, et al. Characteristics and outcomes of children with acute myeloid leukemia and Down syndrome who are ineligible for clinical trials due to severe comorbidities. Pediatr Blood Cancer. 2019;66:e27942 https:\/\/doi.org\/10.1002\/pbc.27942","journal-title":"Pediatr Blood Cancer"}],"updated-by":[{"DOI":"10.1038\/s41375-021-01397-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000}}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01157-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01157-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01157-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T08:20:23Z","timestamp":1630657223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01157-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1157"],"URL":"https:\/\/doi.org\/10.1038\/s41375-021-01157-w","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.739568257.793583242","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"assertion":[{"value":"2 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41375-021-01397-w","URL":"https:\/\/doi.org\/10.1038\/s41375-021-01397-w","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}